Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

For what it’s worth

jbuffett62

Jul 19, 2023 10:06AM

Re: For what it’s worth

KOO-KOO2

Jul 19, 2023 10:40AM

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: For what it’s worth

in response to

Re: For what it’s worth

KOO-KOO2

posted on Jul 19, 2023 05:11PM

KK2 - If memory serves correctly this trial is being done by MSK and paid for by the National Cancer Institute (NIH). Zenith Epigenetics Ltd does not have the funds to do any trials on their own, however the NUT Midline may push that narrative.

There doesn't appear to be anywhere in any descriptors for who is funding any part of the trial.

tada

2 Recommendations

Re: For what it’s worth

tada

Jul 19, 2023 05:13PM

Re: For what it’s worth

KOO-KOO2

Jul 20, 2023 06:52AM

Re: For what it’s worth

jbuffett62

Jul 20, 2023 08:04AM